美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

信息服務

5.19

+0.12002.37%

成交量：15.99萬

成交額：82.86萬

市值：2.51億

市盈率：21.64

高：5.21

開：5.12

低：5.09

收：5.07

52周最高：6.45

52周最低：3.74

股本：4,841.35萬

流通股本：3,555.23萬

量比：0.94

換手率：0.45%

股息：0.18

股息率：3.47%

每股收益(TTM):0.2399

每股收益(LYR):0.1900

淨資產收益率：12.30%

總資產收益率：6.36%

市淨率：2.62

市盈率(LYR):27.32

資料載入中...

總覽公司新聞公告

君實生物(01877)：特瑞普利單抗聯合化療用於II-III期可切除非小細胞肺癌患者圍手術期治療的III期臨床研究達到最終分析主要研究終點

Inovio中國合作伙伴III期試驗成功

环球市场播报

阿斯利康將在ASCO 2026公布多項III期數據，涵蓋肝癌、乳腺癌、膀胱癌及罕見病療法

环球市场播报

港股異動 | 康寧傑瑞製藥-B(09966)升逾5% 恩沃利單抗新適應症III期臨床完成入組

安捷倫推出1290 Infinity III熒光檢測器，實現UHPLC速度下的高信度痕量分析

环球市场播报

思路迪醫藥股份(01244)：恩維達®非小細胞肺癌新輔助╱輔助治療III期臨床研究提前完成入組

Bimzelx頭對頭III期研究告捷，斑塊狀銀屑病關節炎指標顯著優於Skyrizi

环球市场播报

港股異動 | 維立志博-B(09887)早盤升逾4% 維利信™治療晚期肺外神經內分泌癌III期臨床研究獲批

維立志博-B(09887)：維利信™(PD-L1/4-1BB雙特異性抗體奧帕替蘇米單抗，LBL-024)治療晚期肺外神經內分泌癌的III期臨床研究獲得CDE批准

港股異動 | 來凱醫藥-B(02105)午前升逾5% LAE002 III期臨床到達終點將提交上市申請

眾生藥業：公司正在積極推進RAY1225注射液的III期臨床試驗

新股前瞻|大單品進入III期臨床，現金流告急的質肽生物就差臨門一腳？

港股異動 | 銀諾醫藥-B(02591)午前升逾43% Suba的III期減重數據預計2026年年底前公布

翰宇藥業(300199.SZ)：司美格魯肽注射液減重及降糖兩項國內適應症的III期臨床試驗均獲得達到等效標準

銀之傑：實施業務轉型戰略發展互聯網證券信息服務業務

美國懸賞1000萬美元追查伊朗關聯民兵組織頭目

港股異動 | 歌禮制藥-B(01672)午前升逾4% 核心管線ASC30即將啓動III期註冊臨床

康寧傑瑞製藥-B(09966)：KN026新輔助治療乳腺癌III期臨床研究結果獲選於2026 ASCO年會 LBA口頭報告環節進行展示

石藥集團(01093)：注射用西羅莫司(白蛋白結合型)(HB1901)用於治療晚期惡性血管周圍上皮樣細胞瘤(PEComa)的Ib / III期臨床研究達到主要終點

軒竹生物-B(02575)：地羅阿克一線治療ALK陽性晚期非小細胞肺癌III期臨床研究數據於2026年AACR展示

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/III/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"III","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"III\",,,,,undefined,":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服務","latestPrice":5.19,"timestamp":1789156800000,"preClose":5.07,"halted":0,"volume":159870,"delay":0,"changeRate":0.023668639053254458,"floatShares":35552300,"shares":48413462,"eps":0.239856,"marketStatus":"盤前交易","change":0.12,"latestTime":"09-14 06:17:41 EDT","open":5.12,"high":5.2055,"low":5.09,"amount":828609.6472049999,"amplitude":0.022781,"askPrice":5.65,"askSize":407,"bidPrice":3.78,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.239856,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789392600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":5.19,"dividendRate":0.034682,"postHourTrading":{"tag":"盘后","latestPrice":5.1942,"preClose":5.19,"latestTime":"18:01 EDT","volume":6848,"amount":35538.93,"timestamp":1789164063186,"change":0.0042,"changeRate":0.000809,"amplitude":0.000809},"volumeRatio":0.9375505815927984,"impliedVol":1.2381,"impliedVolPercentile":0.524},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"III\",,,,,undefined,":{"symbol":"III","floatShares":35552300,"roa":"6.36%","roe":"12.30%","lyrEps":0.19,"volumeRatio":0.9375505815927984,"shares":48413462,"dividePrice":0.18,"high":5.2055,"amplitude":0.022781,"preClose":5.07,"low":5.09,"week52Low":3.74,"pbRate":"2.62","psRate":"1.00","week52High":6.4495,"institutionHeld":0.6836,"latestPrice":5.19,"committee":-0.605523,"eps":0.239856,"divideRate":0.034682,"volume":159870,"delay":0,"ttmEps":0.239856,"open":5.12,"prevYearClose":5.78,"prevWeekClose":5.19,"prevMonthClose":5.12,"prevQuarterClose":4.11,"fiveDayClose":5.13,"twentyDayClose":5.17,"sixtyDayClose":4.12,"dividendPayoutRate":0.9280598907982862,"dividendFrequency":"Q","dividendGrowthYears":4,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.03333720106347336},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/III\",params:#limit:5,,,undefined,":[{"date":"2026-09-04","symbol":"III","amount":0.045,"announcedDate":"2026-08-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-04","defaultRemindTime":1788528600000,"name":"信息服务","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-25","payableDate":"2026-09-04","currency":"USD","dateTimestamp":1788494400000,"payDate":"2026-09-25"},{"market":"US","date":"2026-08-05","symbol":"III","fiscalQuarterEnding":"2026/06","expectedEps":0.06,"name":null,"time":"盤後","type":"earning","dateTimestamp":1785902400000,"reportTimeType":"post","actualEps":0.07},{"date":"2026-06-05","symbol":"III","amount":0.045,"announcedDate":"2026-05-07","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-05","defaultRemindTime":1780666200000,"name":"信息服务","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-05","currency":"USD","dateTimestamp":1780632000000,"payDate":"2026-06-26"},{"market":"US","date":"2026-05-07","symbol":"III","fiscalQuarterEnding":"2026/03","expectedEps":0.05,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":0.06},{"date":"2026-03-20","symbol":"III","amount":0.045,"announcedDate":"2026-03-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-20","defaultRemindTime":1774013400000,"name":"信息服务","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-26","payableDate":"2026-03-20","currency":"USD","dateTimestamp":1773979200000,"payDate":"2026-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"III\",market:\"US\",,,undefined,":[{"executeDate":"2021-06-03","recordDate":"2021-06-04","paymentDate":"2021-06-18","value":0.03,"currency":"USD"},{"executeDate":"2021-09-03","recordDate":"2021-09-07","paymentDate":"2021-09-24","value":0.03,"currency":"USD"},{"executeDate":"2021-12-02","recordDate":"2021-12-03","paymentDate":"2021-12-17","value":0.03,"currency":"USD"},{"executeDate":"2022-03-18","recordDate":"2022-03-21","paymentDate":"2022-04-06","value":0.03,"currency":"USD"},{"executeDate":"2022-06-02","recordDate":"2022-06-03","paymentDate":"2022-06-17","value":0.04,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"III\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1679457600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/III\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"III","date":"2026-09-11","current":21.637983,"percent":0.61645,"low":-221.876594,"twenty":12.58915,"median":18.223516,"eighty":29.237367,"high":68.328883,"avg":0.809935,"sd":58.867544,"marketCap":245456252},"quantilePoints":[{"date":"2021-09-17","current":33.210859,"twenty":29.540957,"median":36.811685,"eighty":53.929654,"marketCap":366382200},{"date":"2021-09-24","current":32.859422,"twenty":29.540957,"median":36.811685,"eighty":53.929654,"marketCap":362505139},{"date":"2021-10-01","current":31.936898,"twenty":29.540957,"median":36.811685,"eighty":53.929654,"marketCap":352327856},{"date":"2021-10-08","current":33.386578,"twenty":29.603046,"median":36.811685,"eighty":53.929654,"marketCap":368320730},{"date":"2021-10-15","current":31.849038,"twenty":29.673426,"median":36.811685,"eighty":53.929654,"marketCap":351358591},{"date":"2021-10-22","current":33.386578,"twenty":29.768974,"median":36.811685,"eighty":53.929654,"marketCap":368320730},{"date":"2021-10-29","current":35.802712,"twenty":29.76934,"median":36.811685,"eighty":53.929654,"marketCap":394975520},{"date":"2021-11-05","current":32.443868,"twenty":29.838435,"median":36.811685,"eighty":53.929654,"marketCap":434715388},{"date":"2021-11-12","current":34.955794,"twenty":29.845286,"median":36.811685,"eighty":53.929654,"marketCap":468372678},{"date":"2021-11-19","current":34.77297,"twenty":29.845286,"median":36.811685,"eighty":53.929654,"marketCap":465923030},{"date":"2021-11-26","current":30.348649,"twenty":29.845286,"median":36.811685,"eighty":53.929654,"marketCap":406641551},{"date":"2021-12-03","current":28.886064,"twenty":29.82833,"median":36.811685,"eighty":53.929654,"marketCap":387044368},{"date":"2021-12-10","current":29.507663,"twenty":29.768974,"median":36.811685,"eighty":53.929654,"marketCap":395373171},{"date":"2021-12-17","current":26.984703,"twenty":29.661234,"median":36.811685,"eighty":53.929654,"marketCap":361568030},{"date":"2021-12-23","current":28.081642,"twenty":29.603046,"median":36.811685,"eighty":53.929654,"marketCap":376265917},{"date":"2021-12-31","current":27.862254,"twenty":29.504246,"median":36.811685,"eighty":53.929654,"marketCap":373326339},{"date":"2022-01-07","current":26.399668,"twenty":29.437039,"median":36.760945,"eighty":53.927618,"marketCap":353729156},{"date":"2022-01-14","current":25.302729,"twenty":29.255815,"median":36.760945,"eighty":53.927618,"marketCap":339031269},{"date":"2022-01-21","current":23.145416,"twenty":29.125104,"median":36.760945,"eighty":53.927618,"marketCap":310125424},{"date":"2022-01-28","current":22.670075,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":303756339},{"date":"2022-02-04","current":24.863954,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":333152114},{"date":"2022-02-11","current":25.887763,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":346870142},{"date":"2022-02-18","current":27.130961,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":363527748},{"date":"2022-02-25","current":26.107151,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":349809720},{"date":"2022-03-04","current":27.423478,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":367447185},{"date":"2022-03-11","current":22.999463,"twenty":29.042114,"median":36.760945,"eighty":53.927618,"marketCap":357158663},{"date":"2022-03-18","current":22.63323,"twenty":28.930434,"median":36.760945,"eighty":53.927618,"marketCap":351471428},{"date":"2022-03-25","current":21.138876,"twenty":28.720555,"median":36.760945,"eighty":53.927618,"marketCap":328265612},{"date":"2022-04-01","current":21.387935,"twenty":28.563876,"median":36.760945,"eighty":53.927618,"marketCap":332133248},{"date":"2022-04-08","current":20.640759,"twenty":28.47654,"median":36.760945,"eighty":53.927618,"marketCap":320530340},{"date":"2022-04-14","current":20.79642,"twenty":28.362763,"median":36.760945,"eighty":53.927618,"marketCap":322947612},{"date":"2022-04-22","current":19.769052,"twenty":28.214177,"median":36.760945,"eighty":53.927618,"marketCap":306993613},{"date":"2022-04-29","current":19.519993,"twenty":28.004454,"median":36.760945,"eighty":53.927618,"marketCap":303125977},{"date":"2022-05-06","current":18.430361,"twenty":27.931066,"median":36.760945,"eighty":53.927618,"marketCap":286205069},{"date":"2022-05-13","current":17.907825,"twenty":27.846885,"median":36.556933,"eighty":53.927618,"marketCap":305059795},{"date":"2022-05-20","current":17.625134,"twenty":27.555111,"median":36.381032,"eighty":53.927618,"marketCap":300244158},{"date":"2022-05-27","current":18.472496,"twenty":27.379781,"median":36.238493,"eighty":53.927618,"marketCap":314678973},{"date":"2022-06-03","current":18.274778,"twenty":27.167526,"median":36.092994,"eighty":53.927618,"marketCap":311310849},{"date":"2022-06-10","current":16.269354,"twenty":26.614253,"median":35.829538,"eighty":53.927618,"marketCap":277148453},{"date":"2022-06-17","current":16.551809,"twenty":26.372596,"median":35.640231,"eighty":53.822908,"marketCap":281960058},{"date":"2022-06-24","current":17.879343,"twenty":26.107151,"median":35.537925,"eighty":53.79462,"marketCap":304574602},{"date":"2022-07-01","current":19.093895,"twenty":25.975518,"median":35.458953,"eighty":53.271145,"marketCap":325264504},{"date":"2022-07-08","current":19.856521,"twenty":25.412423,"median":35.283172,"eighty":53.041064,"marketCap":338255838},{"date":"2022-07-15","current":19.291613,"twenty":24.849328,"median":35.178625,"eighty":52.906055,"marketCap":328632628},{"date":"2022-07-22","current":20.138975,"twenty":24.08147,"median":35.060591,"eighty":52.665026,"marketCap":343067443},{"date":"2022-07-29","current":21.071074,"twenty":23.209281,"median":34.955794,"eighty":52.523833,"marketCap":358945740},{"date":"2022-08-05","current":21.635982,"twenty":22.947966,"median":34.77297,"eighty":52.322009,"marketCap":368568950},{"date":"2022-08-12","current":16.409925,"twenty":22.628286,"median":34.72983,"eighty":52.322009,"marketCap":293507911},{"date":"2022-08-19","current":16.552576,"twenty":22.371718,"median":34.475053,"eighty":52.322009,"marketCap":296059374},{"date":"2022-08-26","current":16.15211,"twenty":21.544722,"median":34.282985,"eighty":52.322009,"marketCap":288896647},{"date":"2022-09-02","current":14.950714,"twenty":21.183009,"median":34.23369,"eighty":52.322009,"marketCap":267408467},{"date":"2022-09-09","current":14.817225,"twenty":21.074397,"median":34.193624,"eighty":52.322009,"marketCap":265020891},{"date":"2022-09-16","current":14.123085,"twenty":20.842582,"median":34.06831,"eighty":52.322009,"marketCap":252605498},{"date":"2022-09-23","current":12.948386,"twenty":20.628306,"median":33.98562,"eighty":52.322009,"marketCap":231594833},{"date":"2022-09-30","current":12.708107,"twenty":20.189817,"median":33.90293,"eighty":52.322009,"marketCap":227297197},{"date":"2022-10-07","current":12.761502,"twenty":19.975152,"median":33.869805,"eighty":52.322009,"marketCap":228252227},{"date":"2022-10-14","current":12.814898,"twenty":19.650749,"median":33.737549,"eighty":52.322009,"marketCap":229207257},{"date":"2022-10-21","current":13.268758,"twenty":19.370558,"median":33.630766,"eighty":52.322009,"marketCap":237325014},{"date":"2022-10-28","current":14.790528,"twenty":19.172983,"median":33.57217,"eighty":52.322009,"marketCap":264543376},{"date":"2022-11-04","current":11.924698,"twenty":18.940931,"median":33.57217,"eighty":52.322009,"marketCap":226819682},{"date":"2022-11-11","current":14.156908,"twenty":18.67839,"median":33.490051,"eighty":52.100253,"marketCap":269278547},{"date":"2022-11-18","current":14.055967,"twenty":18.383013,"median":33.406789,"eighty":51.591958,"marketCap":267358557},{"date":"2022-11-25","current":13.52603,"twenty":17.941577,"median":33.349337,"eighty":51.184669,"marketCap":257278611},{"date":"2022-12-02","current":13.223208,"twenty":17.811433,"median":33.272057,"eighty":50.857754,"marketCap":251518642},{"date":"2022-12-09","current":12.59233,"twenty":17.329516,"median":33.261363,"eighty":50.482919,"marketCap":239518707},{"date":"2022-12-16","current":11.406279,"twenty":16.879455,"median":33.138265,"eighty":50.207132,"marketCap":216958829},{"date":"2022-12-23","current":11.507219,"twenty":16.612253,"median":33.07907,"eighty":49.781169,"marketCap":218878818},{"date":"2022-12-30","current":11.60816,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":220798808},{"date":"2023-01-06","current":12.264273,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":233278741},{"date":"2023-01-13","current":13.122268,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":249598653},{"date":"2023-01-20","current":12.970857,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":246718668},{"date":"2023-01-27","current":13.122268,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":249598653},{"date":"2023-02-03","current":13.879322,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":263998575},{"date":"2023-02-10","current":13.879322,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":263998575},{"date":"2023-02-17","current":13.677441,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":260158596},{"date":"2023-02-24","current":12.945622,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":246238671},{"date":"2023-03-03","current":13.500795,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":256798614},{"date":"2023-03-10","current":12.166618,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":239998705},{"date":"2023-03-17","current":11.411218,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":225097683},{"date":"2023-03-24","current":12.147425,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":239620114},{"date":"2023-03-31","current":12.490989,"twenty":16.382886,"median":33.063229,"eighty":49.624683,"marketCap":246397249},{"date":"2023-04-06","current":12.294667,"twenty":16.382886,"median":33.063229,"eighty":49.624683,"marketCap":242524601},{"date":"2023-04-14","current":12.687311,"twenty":16.399164,"median":33.067908,"eighty":49.624683,"marketCap":250269897},{"date":"2023-04-21","current":12.270127,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":242040520},{"date":"2023-04-28","current":12.196506,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":240588276},{"date":"2023-05-05","current":12.245586,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":241556438},{"date":"2023-05-12","current":13.473902,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":246397249},{"date":"2023-05-19","current":14.20765,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":259815303},{"date":"2023-05-26","current":13.413927,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":245300481},{"date":"2023-06-02","current":13.387469,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":244816654},{"date":"2023-06-09","current":13.943076,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":254977029},{"date":"2023-06-16","current":14.075363,"twenty":16.45538,"median":33.071968,"eighty":49.624683,"marketCap":257396166},{"date":"2023-06-23","current":15.080746,"twenty":16.529212,"median":33.076029,"eighty":49.624683,"marketCap":275781606},{"date":"2023-06-30","current":14.154735,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":258847648},{"date":"2023-07-07","current":13.810789,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":252557892},{"date":"2023-07-14","current":14.260565,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":260782957},{"date":"2023-07-21","current":14.048906,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":256912338},{"date":"2023-07-28","current":13.387469,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":244816654},{"date":"2023-08-04","current":16.278939,"twenty":16.551809,"median":33.076029,"eighty":49.624683,"marketCap":254977029},{"date":"2023-08-11","current":16.275803,"twenty":16.382336,"median":32.997393,"eighty":49.558778,"marketCap":254927904},{"date":"2023-08-18","current":15.376759,"twenty":16.278939,"median":32.930248,"eighty":49.391703,"marketCap":240846172},{"date":"2023-08-25","current":15.40776,"twenty":16.232204,"median":32.835614,"eighty":49.042233,"marketCap":241331749},{"date":"2023-09-01","current":16.120795,"twenty":16.15211,"median":32.803437,"eighty":48.925743,"marketCap":252500019},{"date":"2023-09-08","current":15.035742,"twenty":16.031821,"median":32.75433,"eighty":48.809254,"marketCap":235504825},{"date":"2023-09-15","current":14.446713,"twenty":15.779779,"median":32.64723,"eighty":48.576274,"marketCap":226278863},{"date":"2023-09-22","current":13.733678,"twenty":15.562768,"median":32.609831,"eighty":48.459784,"marketCap":215110593},{"date":"2023-09-29","current":13.423662,"twenty":15.404575,"median":32.491023,"eighty":48.459784,"marketCap":210254823},{"date":"2023-10-06","current":13.950688,"twenty":15.345757,"median":32.431996,"eighty":48.459784,"marketCap":218509632},{"date":"2023-10-13","current":13.361659,"twenty":15.080746,"median":32.334816,"eighty":48.343294,"marketCap":209283669},{"date":"2023-10-20","current":13.051644,"twenty":14.911736,"median":32.178609,"eighty":48.324535,"marketCap":204427900},{"date":"2023-10-27","current":12.77263,"twenty":14.827387,"median":32.156546,"eighty":48.226804,"marketCap":200057707},{"date":"2023-11-03","current":15.032891,"twenty":14.614323,"median":32.100506,"eighty":48.180208,"marketCap":200057707},{"date":"2023-11-10","current":15.314305,"twenty":14.614323,"median":32.044484,"eighty":48.063719,"marketCap":203802770},{"date":"2023-11-17","current":15.975354,"twenty":14.614323,"median":32.022403,"eighty":47.932458,"marketCap":212600012},{"date":"2023-11-24","current":16.048804,"twenty":14.614323,"median":31.943078,"eighty":47.714249,"marketCap":213577483},{"date":"2023-12-01","current":15.27758,"twenty":14.614323,"median":31.841671,"eighty":47.187487,"marketCap":203314034},{"date":"2023-12-08","current":16.673128,"twenty":14.619662,"median":31.750721,"eighty":46.490677,"marketCap":221885989},{"date":"2023-12-15","current":16.673128,"twenty":14.619662,"median":31.53949,"eighty":46.22662,"marketCap":221885989},{"date":"2023-12-22","current":17.407627,"twenty":14.619662,"median":31.467912,"eighty":45.230776,"marketCap":231660702},{"date":"2023-12-29","current":17.554527,"twenty":14.614323,"median":31.234022,"eighty":45.040598,"marketCap":233615645},{"date":"2024-01-05","current":16.673128,"twenty":14.608983,"median":31.080268,"eighty":44.740412,"marketCap":221885989},{"date":"2024-01-12","current":16.452778,"twenty":14.608983,"median":30.97496,"eighty":44.593596,"marketCap":218953575},{"date":"2024-01-19","current":16.269154,"twenty":14.603644,"median":30.818124,"eighty":44.593596,"marketCap":216509897},{"date":"2024-01-26","current":17.554527,"twenty":14.608983,"median":30.62605,"eighty":44.463847,"marketCap":233615645},{"date":"2024-02-02","current":16.820028,"twenty":14.608983,"median":30.523385,"eighty":44.220503,"marketCap":223840932},{"date":"2024-02-09","current":16.122254,"twenty":14.608983,"median":30.418362,"eighty":43.923358,"marketCap":214554954},{"date":"2024-02-16","current":16.305879,"twenty":14.608983,"median":30.260593,"eighty":43.769861,"marketCap":216998633},{"date":"2024-02-23","current":15.608105,"twenty":14.608983,"median":30.141793,"eighty":42.75327,"marketCap":207712655},{"date":"2024-03-01","current":15.901904,"twenty":14.614323,"median":30.092043,"eighty":42.030433,"marketCap":211622540},{"date":"2024-03-08","current":34.784891,"twenty":14.614323,"median":29.930691,"eighty":41.395649,"marketCap":214066219},{"date":"2024-03-15","current":30.710223,"twenty":14.614323,"median":29.930691,"eighty":41.308941,"marketCap":188990710},{"date":"2024-03-22","current":32.281078,"twenty":14.614323,"median":30.092043,"eighty":41.308941,"marketCap":198657754},{"date":"2024-03-28","current":31.652736,"twenty":14.614323,"median":30.092043,"eighty":41.308941,"marketCap":194790936},{"date":"2024-04-05","current":31.966907,"twenty":14.608983,"median":30.092453,"eighty":41.339259,"marketCap":196724345},{"date":"2024-04-12","current":30.238966,"twenty":14.608983,"median":30.167144,"eighty":41.339259,"marketCap":186090597},{"date":"2024-04-19","current":28.589568,"twenty":14.608983,"median":30.167144,"eighty":41.339259,"marketCap":175940200},{"date":"2024-04-26","current":27.411426,"twenty":14.614323,"median":30.165826,"eighty":41.308941,"marketCap":168689917},{"date":"2024-05-03","current":26.39037,"twenty":14.614323,"median":30.165826,"eighty":41.308941,"marketCap":162406339},{"date":"2024-05-10","current":25.919114,"twenty":14.614323,"median":30.117759,"eighty":41.308941,"marketCap":159506226},{"date":"2024-05-17","current":-211.151442,"twenty":14.503289,"median":29.916131,"eighty":41.308941,"marketCap":153295947},{"date":"2024-05-24","current":-211.151442,"twenty":14.319403,"median":29.768426,"eighty":41.308941,"marketCap":153295947},{"date":"2024-05-31","current":-216.514018,"twenty":14.260565,"median":29.603046,"eighty":41.308941,"marketCap":157189177},{"date":"2024-06-07","current":-209.810798,"twenty":14.204967,"median":29.476834,"eighty":41.308941,"marketCap":152322639},{"date":"2024-06-14","current":-212.492085,"twenty":14.156908,"median":29.278446,"eighty":41.339259,"marketCap":154269254},{"date":"2024-06-21","current":-203.777899,"twenty":14.123085,"median":28.941526,"eighty":41.369578,"marketCap":147942755},{"date":"2024-06-28","current":-205.788865,"twenty":14.101821,"median":28.815898,"eighty":41.369578,"marketCap":149402716},{"date":"2024-07-05","current":-205.118543,"twenty":14.061456,"median":28.592041,"eighty":41.369578,"marketCap":148916062},{"date":"2024-07-12","current":-210.48112,"twenty":13.995991,"median":28.46557,"eighty":41.369578,"marketCap":152809293},{"date":"2024-07-15","current":-211.151442,"twenty":13.995991,"median":28.446337,"eighty":41.369578,"marketCap":153295947},{"date":"2024-08-02","current":-221.876594,"twenty":13.965764,"median":28.594514,"eighty":41.395649,"marketCap":161082407},{"date":"2024-08-09","current":-155.153276,"twenty":13.890161,"median":28.447288,"eighty":41.369578,"marketCap":158411495},{"date":"2024-08-16","current":-157.547617,"twenty":13.879322,"median":28.196854,"eighty":41.040322,"marketCap":160856117},{"date":"2024-08-23","current":-158.026486,"twenty":13.823503,"median":28.008512,"eighty":39.690077,"marketCap":161345042},{"date":"2024-08-30","current":-166.167244,"twenty":13.795681,"median":27.935383,"eighty":38.544,"marketCap":169656756},{"date":"2024-09-06","current":-154.195541,"twenty":13.753035,"median":27.569737,"eighty":38.347232,"marketCap":157433647},{"date":"2024-09-13","current":-151.322331,"twenty":13.704502,"median":27.313784,"eighty":38.122137,"marketCap":154500100},{"date":"2024-09-20","current":-156.111013,"twenty":13.672394,"median":27.130961,"eighty":37.980944,"marketCap":159389344},{"date":"2024-09-27","current":-154.195541,"twenty":13.62697,"median":26.595041,"eighty":37.894382,"marketCap":157433647},{"date":"2024-10-04","current":-155.153276,"twenty":13.599214,"median":26.468913,"eighty":37.779744,"marketCap":158411495},{"date":"2024-10-11","current":-150.364595,"twenty":13.553316,"median":26.233285,"eighty":37.589923,"marketCap":153522252},{"date":"2024-10-18","current":-152.280068,"twenty":13.524775,"median":26.107151,"eighty":37.433759,"marketCap":155477949},{"date":"2024-10-25","current":-147.012518,"twenty":13.48942,"median":25.919114,"eighty":37.27024,"marketCap":150099781},{"date":"2024-10-31","current":-150.364595,"twenty":13.450324,"median":25.485552,"eighty":37.015362,"marketCap":153522252},{"date":"2024-11-08","current":-52.964156,"twenty":13.423662,"median":24.845672,"eighty":36.750798,"marketCap":162811815},{"date":"2024-11-15","current":-53.318651,"twenty":13.387469,"median":24.004684,"eighty":36.556933,"marketCap":163901532},{"date":"2024-11-22","current":-53.238832,"twenty":13.341574,"median":23.198637,"eighty":36.327656,"marketCap":163656170},{"date":"2024-11-29","current":-58.905934,"twenty":13.314055,"median":22.981027,"eighty":36.238493,"marketCap":181076842},{"date":"2024-12-06","current":-58.267387,"twenty":13.27171,"median":22.651653,"eighty":35.999189,"marketCap":179113949},{"date":"2024-12-13","current":-58.427024,"twenty":13.239501,"median":22.455197,"eighty":35.783905,"marketCap":179604672},{"date":"2024-12-20","current":-55.074654,"twenty":13.19425,"median":21.621859,"eighty":35.607032,"marketCap":169299486},{"date":"2024-12-27","current":-53.957197,"twenty":13.130069,"median":21.342486,"eighty":35.505726,"marketCap":165864424},{"date":"2025-01-03","current":-51.88192,"twenty":13.070245,"median":21.138876,"eighty":35.459393,"marketCap":159485023},{"date":"2025-01-10","current":-49.96628,"twenty":13.021327,"median":20.901601,"eighty":35.211692,"marketCap":153596345},{"date":"2025-01-17","current":-51.88192,"twenty":12.972548,"median":20.664813,"eighty":35.117714,"marketCap":159485023},{"date":"2025-01-24","current":-51.562647,"twenty":12.952487,"median":20.578494,"eighty":35.032487,"marketCap":158503577},{"date":"2025-01-31","current":-49.168097,"twenty":12.915203,"median":20.138975,"eighty":34.93156,"marketCap":151142730},{"date":"2025-02-07","current":-51.083737,"twenty":12.802486,"median":19.831317,"eighty":34.780123,"marketCap":157031408},{"date":"2025-02-14","current":-51.40301,"twenty":12.725025,"median":19.519993,"eighty":34.72983,"marketCap":158012854},{"date":"2025-02-21","current":-49.48737,"twenty":12.667751,"median":19.333199,"eighty":34.575342,"marketCap":152124176},{"date":"2025-02-28","current":-49.00846,"twenty":12.601316,"median":19.122141,"eighty":34.324158,"marketCap":150652007},{"date":"2025-03-07","current":53.583718,"twenty":12.589786,"median":18.928478,"eighty":34.23369,"marketCap":152124176},{"date":"2025-03-14","current":56.52218,"twenty":12.589786,"median":18.928478,"eighty":34.23369,"marketCap":160466470},{"date":"2025-03-21","current":63.229713,"twenty":12.589786,"median":18.928478,"eighty":34.39907,"marketCap":179509154},{"date":"2025-03-28","current":64.079574,"twenty":12.589786,"median":18.928478,"eighty":34.546571,"marketCap":181921911},{"date":"2025-04-04","current":63.569657,"twenty":12.589786,"median":18.928478,"eighty":34.686729,"marketCap":180474257},{"date":"2025-04-11","current":60.17021,"twenty":12.590422,"median":18.990743,"eighty":34.733776,"marketCap":170823227},{"date":"2025-04-17","current":62.889768,"twenty":12.590422,"median":18.990743,"eighty":34.814432,"marketCap":178544051},{"date":"2025-04-25","current":62.379851,"twenty":12.589786,"median":18.928478,"eighty":34.943677,"marketCap":177096396},{"date":"2025-05-02","current":64.589491,"twenty":12.589786,"median":18.928478,"eighty":34.985212,"marketCap":183369566},{"date":"2025-05-09","current":25.015629,"twenty":12.589786,"median":18.928478,"eighty":35.046539,"marketCap":193020596},{"date":"2025-05-16","current":29.987043,"twenty":12.589786,"median":18.928478,"eighty":34.985212,"marketCap":231380025},{"date":"2025-05-23","current":29.29984,"twenty":12.589786,"median":18.928478,"eighty":34.985212,"marketCap":226077566},{"date":"2025-05-30","current":29.237367,"twenty":12.589786,"median":18.928478,"eighty":34.985212,"marketCap":225595524},{"date":"2025-06-06","current":29.424786,"twenty":12.589786,"median":18.928478,"eighty":34.964732,"marketCap":227041650},{"date":"2025-06-13","current":29.862097,"twenty":12.589786,"median":18.928478,"eighty":34.964732,"marketCap":230415942},{"date":"2025-06-20","current":29.612205,"twenty":12.58915,"median":18.866214,"eighty":34.964732,"marketCap":228487775},{"date":"2025-06-27","current":28.862529,"twenty":12.58915,"median":18.866214,"eighty":34.964732,"marketCap":222703274},{"date":"2025-07-03","current":31.923706,"twenty":12.58915,"median":18.866214,"eighty":34.955794,"marketCap":246323318},{"date":"2025-07-11","current":31.486395,"twenty":12.58915,"median":18.866214,"eighty":34.955794,"marketCap":242949026},{"date":"2025-07-18","current":29.237367,"twenty":12.58915,"median":18.866214,"eighty":34.89521,"marketCap":225595524},{"date":"2025-07-25","current":28.425218,"twenty":12.58915,"median":18.866214,"eighty":34.834126,"marketCap":219328982},{"date":"2025-08-01","current":26.925866,"twenty":12.58915,"median":18.866214,"eighty":34.784891,"marketCap":207759981},{"date":"2025-08-08","current":25.754678,"twenty":12.58915,"median":18.866214,"eighty":34.77297,"marketCap":202457522},{"date":"2025-08-15","current":30.470866,"twenty":12.58915,"median":18.866214,"eighty":34.704469,"marketCap":239531480},{"date":"2025-08-22","current":29.489913,"twenty":12.58915,"median":18.866214,"eighty":34.221243,"marketCap":231820205},{"date":"2025-08-29","current":31.39051,"twenty":12.58915,"median":18.866214,"eighty":34.114807,"marketCap":246760801},{"date":"2025-09-05","current":32.432773,"twenty":12.58915,"median":18.85295,"eighty":34.118522,"marketCap":254954031},{"date":"2025-09-12","current":32.126225,"twenty":12.58915,"median":18.866214,"eighty":34.114807,"marketCap":252544257},{"date":"2025-09-19","current":33.965513,"twenty":12.58915,"median":18.866214,"eighty":34.114807,"marketCap":267002898},{"date":"2025-09-26","current":35.314324,"twenty":12.58915,"median":18.866214,"eighty":34.309102,"marketCap":277605901},{"date":"2025-10-03","current":34.639918,"twenty":12.58915,"median":18.866214,"eighty":34.639918,"marketCap":272304399},{"date":"2025-10-10","current":33.842894,"twenty":12.58915,"median":18.866214,"eighty":34.704469,"marketCap":266038988},{"date":"2025-10-17","current":33.413727,"twenty":12.58915,"median":18.866214,"eighty":34.704469,"marketCap":262665306},{"date":"2025-10-24","current":34.088132,"twenty":12.58915,"median":18.866214,"eighty":34.704469,"marketCap":267966807},{"date":"2025-10-31","current":33.536346,"twenty":12.58915,"median":18.866214,"eighty":34.748399,"marketCap":263629215},{"date":"2025-11-07","current":28.380485,"twenty":12.58915,"median":18.866214,"eighty":34.701228,"marketCap":277248962},{"date":"2025-11-14","current":25.733601,"twenty":12.58915,"median":18.866214,"eighty":34.517299,"marketCap":251391546},{"date":"2025-11-21","current":24.557208,"twenty":12.58915,"median":18.866214,"eighty":34.309102,"marketCap":239899361},{"date":"2025-11-28","current":26.370814,"twenty":12.58915,"median":18.866214,"eighty":34.210751,"marketCap":257616479},{"date":"2025-12-05","current":28.282453,"twenty":12.58915,"median":18.866214,"eighty":33.965513,"marketCap":276291280},{"date":"2025-12-12","current":29.409829,"twenty":12.58915,"median":18.866214,"eighty":33.842894,"marketCap":287304624},{"date":"2025-12-19","current":29.26278,"twenty":12.58915,"median":18.866214,"eighty":33.529773,"marketCap":285868100},{"date":"2025-12-26","current":29.066715,"twenty":12.58915,"median":18.866214,"eighty":33.430508,"marketCap":283952736},{"date":"2026-01-02","current":28.331469,"twenty":12.58915,"median":18.866214,"eighty":33.342648,"marketCap":276770121},{"date":"2026-01-09","current":29.164747,"twenty":12.58915,"median":18.866214,"eighty":33.210859,"marketCap":284910418},{"date":"2026-01-16","current":29.80196,"twenty":12.58915,"median":18.866214,"eighty":33.054432,"marketCap":291135352},{"date":"2026-01-23","current":27.792289,"twenty":12.58915,"median":18.866214,"eighty":32.903351,"marketCap":271502869},{"date":"2026-01-30","current":27.400158,"twenty":12.58915,"median":18.866214,"eighty":32.739321,"marketCap":267672141},{"date":"2026-02-06","current":24.998355,"twenty":12.58915,"median":18.866214,"eighty":32.548436,"marketCap":244208930},{"date":"2026-02-13","current":22.35147,"twenty":12.58915,"median":18.866214,"eighty":32.359621,"marketCap":218351514},{"date":"2026-02-20","current":22.841634,"twenty":12.58915,"median":18.866214,"eighty":32.126225,"marketCap":223139924},{"date":"2026-02-27","current":23.429831,"twenty":12.58915,"median":18.866214,"eighty":32.068687,"marketCap":228886017},{"date":"2026-03-06","current":24.400849,"twenty":12.58915,"median":18.866214,"eighty":31.936898,"marketCap":227928335},{"date":"2026-03-13","current":20.466129,"twenty":12.58915,"median":18.866214,"eighty":31.809821,"marketCap":191174107},{"date":"2026-03-20","current":19.649525,"twenty":12.58915,"median":18.866214,"eighty":31.731279,"marketCap":183546212},{"date":"2026-03-27","current":19.7516,"twenty":12.58915,"median":18.866214,"eighty":31.635749,"marketCap":184499699},{"date":"2026-04-02","current":19.598487,"twenty":12.58915,"median":18.866214,"eighty":31.486395,"marketCap":183069469},{"date":"2026-04-10","current":20.415091,"twenty":12.58915,"median":18.866214,"eighty":31.417108,"marketCap":190697364},{"date":"2026-04-17","current":21.282732,"twenty":12.58915,"median":18.866214,"eighty":31.338565,"marketCap":198802001},{"date":"2026-04-24","current":20.466129,"twenty":12.58915,"median":18.866214,"eighty":31.102233,"marketCap":191174107},{"date":"2026-05-01","current":20.823393,"twenty":12.58915,"median":18.866214,"eighty":30.970444,"marketCap":194511311},{"date":"2026-05-08","current":18.809916,"twenty":12.58915,"median":18.839687,"eighty":30.838724,"marketCap":198802001},{"date":"2026-05-15","current":19.2371,"twenty":12.58915,"median":18.809916,"eighty":30.611773,"marketCap":203316914},{"date":"2026-05-22","current":19.780266,"twenty":12.58915,"median":18.739199,"eighty":30.409557,"marketCap":209057627},{"date":"2026-05-29","current":20.504486,"twenty":12.58915,"median":18.718829,"eighty":30.267569,"marketCap":216711911},{"date":"2026-06-05","current":19.644474,"twenty":12.58915,"median":18.739199,"eighty":30.174462,"marketCap":207622449},{"date":"2026-06-12","current":19.372892,"twenty":12.58915,"median":18.739199,"eighty":30.111989,"marketCap":204752092},{"date":"2026-06-18","current":18.829726,"twenty":12.58915,"median":18.698459,"eighty":29.987245,"marketCap":199011379},{"date":"2026-06-26","current":18.377089,"twenty":12.58915,"median":18.492688,"eighty":29.953208,"marketCap":194227452},{"date":"2026-07-02","current":18.965518,"twenty":12.58915,"median":18.492688,"eighty":29.862097,"marketCap":200446558},{"date":"2026-07-10","current":18.422353,"twenty":12.58915,"median":18.42051,"eighty":29.749013,"marketCap":194705845},{"date":"2026-07-17","current":18.558144,"twenty":12.58915,"median":18.377089,"eighty":29.67784,"marketCap":196141023},{"date":"2026-07-24","current":17.381286,"twenty":12.58915,"median":18.28067,"eighty":29.612205,"marketCap":183702812},{"date":"2026-07-31","current":18.648671,"twenty":12.58915,"median":18.223516,"eighty":29.51755,"marketCap":197097808},{"date":"2026-08-07","current":20.47213,"twenty":12.58915,"median":18.223516,"eighty":29.481004,"marketCap":239196370},{"date":"2026-08-14","current":21.422252,"twenty":12.58915,"median":18.223516,"eighty":29.444258,"marketCap":250297598},{"date":"2026-08-21","current":20.427796,"twenty":12.58915,"median":18.223516,"eighty":29.415812,"marketCap":238678367},{"date":"2026-08-28","current":20.883588,"twenty":12.58915,"median":18.223516,"eighty":29.304623,"marketCap":244003848},{"date":"2026-09-04","current":21.25651,"twenty":12.58915,"median":18.223516,"eighty":29.26278,"marketCap":248361060},{"date":"2026-09-11","current":21.007896,"twenty":12.58915,"median":18.223516,"eighty":29.237367,"marketCap":245456252}],"updateTime":1789358731170},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"III\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2638836543","title":"君實生物(01877)：特瑞普利單抗聯合化療用於II-III期可切除非小細胞肺癌患者圍手術期治療的III期臨床研究達到最終分析主要研究終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2638836543","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638836543?lang=zh_tw&edition=fundamental","pubTime":"2026-05-26 22:21","pubTimestamp":1779805291,"startTime":"0","endTime":"0","summary":"公司计划将于近期向监管部门递交该产品的补充申请，申请适应症由可切除III期非小细胞肺癌患者围手术期治疗扩展为可切除II-III期非小细胞肺癌患者围手术期治疗。截至本公告披露日，特瑞普利单抗的13项适应症已于中国内地获批。特瑞普利单抗用于晚期鼻咽癌和食管鳞癌治疗的3项适应症已在中国香港获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK1161","BK1515","01877","BK1583","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637634193","title":"Inovio中國合作伙伴III期試驗成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2637634193","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637634193?lang=zh_tw&edition=fundamental","pubTime":"2026-05-23 03:31","pubTimestamp":1779478260,"startTime":"0","endTime":"0","summary":"Inovio Pharmaceuticals股价走高，此前其中国合作伙伴ApolloBio在治疗宫颈不典型增生的治疗性DNA疫苗VGX-3100的III期关键性试验中取得成功。该试验达到了第36周复合缓解率的主要终点。Inovio于2018年将VGX-3100授权给ApolloBio，后者承担开发费用，Inovio有权获得最高2000万美元的监管里程碑付款及大中华区净销售额的双位数分层特许权使用费。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-23/doc-inhyvhua5796224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637334314","title":"阿斯利康將在ASCO 2026公布多項III期數據，涵蓋肝癌、乳腺癌、膀胱癌及罕見病療法","url":"https://stock-news.laohu8.com/highlight/detail?id=2637334314","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637334314?lang=zh_tw&edition=fundamental","pubTime":"2026-05-22 23:33","pubTimestamp":1779463980,"startTime":"0","endTime":"0","summary":"阿斯利康于5月22日宣布，将在5月29日至6月2日举行的2026年美国临床肿瘤学会年会上，公布超过85篇摘要，涵盖10款已获批药物和13款潜在新药，其中包括25项口头报告。　　在肝癌方面，将公布EMERALD-3 III期试验结果。　　在膀胱癌方面，将公布POTOMAC III期试验的5年总生存期分析，该试验评估了Imfinzi联合卡介苗治疗高危非肌层浸润性膀胱癌的疗效。　　在罕见病方面，将展示anselamimab的III期临床项目数据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-22/doc-inhyuwee5028220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["III","LU2237443549.SGD","LU2417539215.USD","LU0058720904.USD","LU2237443895.HKD","LU2456880835.USD","BK4007","LU2237443465.HKD","AZNH","LU0320765992.SGD","LU0289739699.SGD","LU0109394709.USD","LU0889565916.HKD","BK4585","AZN","LU2237443622.USD","BK4134","LU2236285917.USD","IE00B3T34201.USD","LU2237443382.USD","LU2462157665.USD","LU1829250122.USD","LU2237443978.SGD","BK4568","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637362263","title":"港股異動 | 康寧傑瑞製藥-B(09966)升逾5% 恩沃利單抗新適應症III期臨床完成入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2637362263","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637362263?lang=zh_tw&edition=fundamental","pubTime":"2026-05-22 11:31","pubTimestamp":1779420681,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康宁杰瑞制药-B涨超4%，截至发稿，涨4.32%，报9.18港元，成交额811.35万港元。消息面上，5月22日，康宁杰瑞生物制药宣布，恩维达新辅助/辅助治疗可切除非小细胞肺癌的Ⅲ期临床研究，已完成全部患者入组。这一里程碑标志着恩维达在早期肺癌围手术期治疗领域取得重要进展，有望为肺癌患者带来更便捷、更安全的皮下免疫治疗新方案。目前恩维达还有多个临床研究在进行中，进一步拓展适应症。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444926.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1161","VXUS","III","BK4588","BK1574","BK4134","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637334485","title":"安捷倫推出1290 Infinity III熒光檢測器，實現UHPLC速度下的高信度痕量分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2637334485","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637334485?lang=zh_tw&edition=fundamental","pubTime":"2026-05-21 22:07","pubTimestamp":1779372420,"startTime":"0","endTime":"0","summary":"安捷伦科技公司宣布推出Agilent 1290 Infinity III荧光检测器。这款新型检测器专为现代超高效液相色谱工作流程设计，将荧光检测技术带入UHPLC时代，为实验室提供痕量分析所需的更高置信度。传统荧光检测器并非为UHPLC方法的窄峰和快速分离而设计。1290 Infinity III FLD通过专为现代UHPLC优化的设计填补了这一空白。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-21/doc-inhysnxc6275941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637336990","title":"思路迪醫藥股份(01244)：恩維達®非小細胞肺癌新輔助╱輔助治療III期臨床研究提前完成入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2637336990","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637336990?lang=zh_tw&edition=fundamental","pubTime":"2026-05-21 20:43","pubTimestamp":1779367407,"startTime":"0","endTime":"0","summary":"智通财经APP讯，思路迪医药股份 发布公告，本公司与康宁杰瑞生物制药共同开发的恩维达用于可切除非小细胞肺癌患者新辅助╱辅助治疗的随机、对照、双盲、多中心III期临床研究已提前完成入组。本次III期临床研究由天津医科大学肿瘤医院王长利教授担任主要研究者，在全国约60家临床研究中心开展，计划入组约390例可切除III期非小细胞肺癌患者，实际入组人数符合研究方案要求，已提前完成入组工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444708.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK1161","III","01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636285087","title":"Bimzelx頭對頭III期研究告捷，斑塊狀銀屑病關節炎指標顯著優於Skyrizi","url":"https://stock-news.laohu8.com/highlight/detail?id=2636285087","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636285087?lang=zh_tw&edition=fundamental","pubTime":"2026-05-19 23:01","pubTimestamp":1779202886,"startTime":"0","endTime":"0","summary":"　　比利时生物制药企业优时比公布了其IL-17A/IL-17F抑制剂Bimzelx的III期BE BOLD研究详细数据。结果显示，Bimzelx在治疗活动性银屑病关节炎患者的关键指标上，击败了艾伯维的重磅IL-23抑制剂Skyrizi。早在治疗第4周，Bimzelx组达到ACR50的患者比例便显著高于Skyrizi组。Bimzelx治疗组念珠菌感染的发生率较高，但均为轻中度，未导致停药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-19/doc-inhymytc2158400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636863428","title":"港股異動 | 維立志博-B(09887)早盤升逾4% 維利信™治療晚期肺外神經內分泌癌III期臨床研究獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2636863428","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636863428?lang=zh_tw&edition=fundamental","pubTime":"2026-05-19 09:53","pubTimestamp":1779155590,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B早盘涨超4%，截至发稿，涨3.21%，报64.35港元，成交额897.51万港元。消息面上，5月19日，维立志博-B发布公告，中华人民共和国国家药品监督管理局药品审评中心已批准开展评价维利信联合含铂化疗作为一线治疗在晚期肺外神经内分泌癌患者中的确证性III期临床研究。该研究获批是基于奥帕替苏米单抗在Ib/II期概念验证性研究中所展现的突破性疗效与良好安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","09887","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","III","VXUS","BK4585","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636022270","title":"維立志博-B(09887)：維利信™(PD-L1/4-1BB雙特異性抗體奧帕替蘇米單抗，LBL-024)治療晚期肺外神經內分泌癌的III期臨床研究獲得CDE批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636022270","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636022270?lang=zh_tw&edition=fundamental","pubTime":"2026-05-19 07:18","pubTimestamp":1779146304,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，中华人民共和国国家药品监督管理局药品审评中心已批准开展评价维利信联合含铂化疗作为一线治疗在晚期肺外神经内分泌癌患者中的确证性III期临床研究。该研究获批是基于奥帕替苏米单抗在Ib/II期概念验证性研究中所展现的突破性疗效与良好安全性。奥帕替苏米单抗已在肺外神经内分泌癌、非小细胞肺癌、小细胞肺癌及胆道癌四个适应症的注册性或II 期临床试验中展示出全球首创或同类最优潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","CDE","PD","HK0000500386.USD","BK4134","LU1169590202.USD","09887","LU1223082196.USD","BK4017","HK0000252152.HKD","HK0000252160.HKD","BK1161","LU1223083913.SGD","LU1169589451.USD","BK4023","LU1223082519.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635761328","title":"港股異動 | 來凱醫藥-B(02105)午前升逾5% LAE002 III期臨床到達終點 將提交上市申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2635761328","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635761328?lang=zh_tw&edition=fundamental","pubTime":"2026-05-14 11:58","pubTimestamp":1778731118,"startTime":"0","endTime":"0","summary":"消息面上，来凯医药核心产品AKT抑制剂LAE002治疗乳腺癌的III期临床试验已于4月15日宣布达到主要终点。根据公司计划，将协同合作伙伴齐鲁制药于近期向国家药监局提交新药上市申请。齐鲁制药也于4月30日宣布将推进该药的国内上市申请。作为回报，若LAE002在中国获批首个适应症，来凯医药有权获得5.3亿元不可退还的首付款与总计最高20.45亿元的里程碑款项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441599.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","02105","BK1161","IPOS","BK4588","VXUS","BK4585","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635750797","title":"眾生藥業：公司正在積極推進RAY1225注射液的III期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2635750797","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635750797?lang=zh_tw&edition=fundamental","pubTime":"2026-05-14 08:51","pubTimestamp":1778719865,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)05月13日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的RAY1225创新三期试验进展如何？减重版三期试验什么时间全部结束？读取数据大概需要多长时间？众生药业回复：您好！公司正在积极推进RAY1225注射液的III期临床试验，有关创新药的进展情况请以公司公告为准。谢谢！为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260514/32223258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["III","002317","BK0239","BK0188","BK4134","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635278901","title":"新股前瞻|大單品進入III期臨床，現金流告急的質肽生物就差臨門一腳？","url":"https://stock-news.laohu8.com/highlight/detail?id=2635278901","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635278901?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 10:23","pubTimestamp":1778639015,"startTime":"0","endTime":"0","summary":"目前，该药物正在中国开展减重II期临床，有望填补口服多肽GLP-1市场空白。公司已于2026年1月在中国完成了ZT002用于肥胖症治疗的III期临床试验的首例患者入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","159399","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634476449","title":"港股異動 | 銀諾醫藥-B(02591)午前升逾43% Suba的III期減重數據預計2026年年底前公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2634476449","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634476449?lang=zh_tw&edition=fundamental","pubTime":"2026-05-11 11:37","pubTimestamp":1778470647,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，银诺医药-B午前涨超43%，截至发稿，涨42.21%，报17.99港元，成交额1.73亿港元。消息面上，银诺医药年度业绩显示，2025 年实现收入1.32亿元，亏损3.41亿元。值得注意的是，银诺医药基石投资者的禁售期将于2026年5月14日届满，相关股份将于5月15日正式解禁流通。Suba的III期减重数据预计2026年年底前公布。治疗肥胖及超重的III期临床研究，已于2025年完成患者入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","III","BK1161","VXUS","02591","BK4134","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633182090","title":"翰宇藥業(300199.SZ)：司美格魯肽注射液減重及降糖兩項國內適應症的III期臨床試驗均獲得達到等效標準","url":"https://stock-news.laohu8.com/highlight/detail?id=2633182090","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633182090?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 19:13","pubTimestamp":1778065991,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布公告，近日，公司司美格鲁肽注射液取得了III期临床数据，数据显示，该药物的减重及降糖两项国内适应症的III期临床试验均获得了达到等效标准。公司司美格鲁肽注射液在国内进行了两项临床试验，分别是：一项在二甲双胍单药治疗血糖控制不佳的2型糖尿病患者中比较HY310注射液与诺和泰®治疗32周的疗效和安全性的多中心、随机、开放设计的III期临床研究。一项在肥胖患者中比较HY310注射液与诺和盈®治疗44周的疗效和安全性的多中心、随机、开放设计的III期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438679.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK0077","BK0028","BK0188","BK0239","III","BK0070","300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630478323","title":"銀之傑：實施業務轉型戰略發展互聯網證券信息服務業務","url":"https://stock-news.laohu8.com/highlight/detail?id=2630478323","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630478323?lang=zh_tw&edition=fundamental","pubTime":"2026-04-28 09:32","pubTimestamp":1777339944,"startTime":"0","endTime":"0","summary":"证券之星消息，银之杰04月27日在投资者关系平台上答复投资者关心的问题。为了改善公司经营情况，提升经营业绩，公司正在实施业务转型战略。主要是基于公司自身产业布局条件，通过引进战略股东，将公司的产业布局优势和战略股东的资源和经验优势相结合，发展互联网证券信息服务业务，进一步夯实公司以金融科技为核心的主营业务。具体进展，请留意公司定期报告披露的内容。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/28/20260428865556.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/28/20260428865556.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260428/32182907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0095","III","BK0231","300085","161027","159792","160636","BK0032","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121648208","title":"美國懸賞1000萬美元追查伊朗關聯民兵組織頭目","url":"https://stock-news.laohu8.com/highlight/detail?id=1121648208","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121648208?lang=zh_tw&edition=fundamental","pubTime":"2026-04-24 12:33","pubTimestamp":1777005200,"startTime":"0","endTime":"0","summary":"美国宣布对伊拉克境内伊朗支持的民兵组织\"烈士旅\"（KSS）头目信息提供最高1000万美元赏金。\n美国国务院\"正义赏金\"项目在社交媒体公告中指出，哈希姆·菲尼安·拉希姆·萨拉吉被确认为该组织的领导人兼秘书长。公告披露，该组织成员\"曾杀害伊拉克平民，袭击美国在伊拉克的外交设施，并对美军在伊拉克和叙利亚的军事基地及人员发动攻击\"。\n去年美国已将烈士旅列为外国恐怖组织。美方当时指出，伊朗通过训练、资金和精密武器等多种形式对该组织提供支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629896382","title":"港股異動 | 歌禮制藥-B(01672)午前升逾4% 核心管線ASC30即將啓動III期註冊臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2629896382","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629896382?lang=zh_tw&edition=fundamental","pubTime":"2026-04-24 11:10","pubTimestamp":1777000213,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B午前涨超4%，截至发稿，涨3.46%，报18.82港元，成交额2199.1万港元。消息面上，歌礼制药此前宣布启动ASC30_39FDC的临床开发，并计划于今年第三季度向美国FDA递交IND申请。口服剂型即将向FDA提交III期临床计划，公司预计将在2026年Q3正式启动。值得注意的是，智通财经APP在《歌礼制药-B：股价突破前高在即，场外资金为何选择观望？》中指出，礼来Orforglipron已于今年4月1日获FDA批准上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","01672","BK1191","BK4585","VXUS","BK4134","01477","BK1161","BK1515","BK1574","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629096535","title":"康寧傑瑞製藥-B(09966)：KN026新輔助治療乳腺癌III期臨床研究結果獲選於2026 ASCO年會 LBA口頭報告環節進行展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2629096535","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629096535?lang=zh_tw&edition=fundamental","pubTime":"2026-04-22 12:03","pubTimestamp":1776830598,"startTime":"0","endTime":"0","summary":"KN026-004是一项随机、对照、开放、多中心III期临床研究，旨在评价KN026 联合HB1801±卡铂对比曲妥珠单抗联合帕妥珠单抗及多西他赛±卡铂在HER2阳性早期及局部晚期BC新辅助治疗中的疗效和安全性。KN026联合疗法有望成为HER2阳性早期及局部晚期BC新辅助治疗的全新标准疗法。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09966","BK1161","III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628749960","title":"石藥集團(01093)：注射用西羅莫司(白蛋白結合型)(HB1901)用於治療晚期惡性血管周圍上皮樣細胞瘤(PEComa)的Ib / III期臨床研究達到主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2628749960","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628749960?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 17:51","pubTimestamp":1776678667,"startTime":"0","endTime":"0","summary":"HB1901表现出优异疗效，有望填补国内该适应症治疗空白，成为国内晚期恶性PEComa首款标准治疗方案。约50 %的恶性PEComa患者确诊时已属晚期，此时常合并转移，预后差。HB1901 -004是一项旨在评价注射用西罗莫司在晚期恶性PEComa患者中安全性与有效性的Ib / III期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YR35.GBP","BK4134","LU1807302812.USD","BK1191","IE0008368742.USD","LU0880133367.SGD","BK1515","LU1226288253.USD","LU1960683339.HKD","LU1226288170.HKD","01093","IE00B031HY20.USD","LU0067412154.USD","IE00B543WZ88.USD","BK1521","IE00B5MMRT66.SGD","LU0072913022.USD","LU1993786604.SGD","LU1152091168.USD","LU1226287875.USD","III","LU1226287792.SGD","LU1226287529.USD","LU1328277881.USD","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","LU0315179316.USD","LU0326950275.SGD","LU0314109678.HKD","LU2039709279.SGD","SG9999004220.SGD","HK0000165453.HKD","LU0140636845.USD","LU1813983027.USD","LU1008478684.HKD","IE0008369823.USD","LU1152091754.HKD","LU1951186391.HKD","LU0501845795.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628615057","title":"軒竹生物-B(02575)：地羅阿克一線治療ALK陽性晚期非小細胞肺癌III期臨床研究數據於2026年AACR展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2628615057","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628615057?lang=zh_tw&edition=fundamental","pubTime":"2026-04-19 18:17","pubTimestamp":1776593868,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，集团已在2026年4月17日至2026年4月22日举行的2026年美国癌症研究协会年会以口头报告的形式展示地罗阿克一线治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌的临床III期研究结果。DIAMOND-2研究是一项在中国境内开展的多中心、随机、开放标签的III期临床研究，以克唑替尼作为对照，旨在头对头评估地罗阿克相较克唑替尼在一线治疗ALK阳性晚期NSCLC患者的有效性与安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ALK","02575","BK4588","BK1191","BK4134","BK4008","BK4500","III","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":7,"totalSize":176,"code":"91000000","status":"200"}]}}